Cargando…
Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach
To evaluate the effects of intravitreal triamcinolone acetonide (TA) as a monotherapy of serous Pigment Epithelial Detachment (PED) associated with AMD (Age-Related Macular Degeneration), this study has been performed. Seventeen patients (19 eyes) with serous PED associated with AMD were observed. A...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medical Hypothesis, Discovery & Innovation Ophthalmology
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939730/ https://www.ncbi.nlm.nih.gov/pubmed/24600628 |
_version_ | 1782305732336549888 |
---|---|
author | V. Pasyechnikova, Nataliya A. Naumenko, Volodymyr R. Korol, Andrii S. Zadorozhnyy, Oleg B. Kustrin, Taras O. Nasinnyk, Illya |
author_facet | V. Pasyechnikova, Nataliya A. Naumenko, Volodymyr R. Korol, Andrii S. Zadorozhnyy, Oleg B. Kustrin, Taras O. Nasinnyk, Illya |
author_sort | V. Pasyechnikova, Nataliya |
collection | PubMed |
description | To evaluate the effects of intravitreal triamcinolone acetonide (TA) as a monotherapy of serous Pigment Epithelial Detachment (PED) associated with AMD (Age-Related Macular Degeneration), this study has been performed. Seventeen patients (19 eyes) with serous PED associated with AMD were observed. All patients received 0.1ml (4mg) of intravitreal TA. The mean follow-up period was 18 months. Re-attachment of serous PED was observed in 37% of cases to the end of follow-up. In other cases, the height and length of serous PED significantly decreased. Visual acuity remained stable in all cases. No evidence of RPE tear or CNV development were noted. Before TA administration, intraocular pressure (IOP) was 20.18 ± 2.58 mmHg however, after intravitreal TA, IOP increased gradually and reached its maximum of all period of observation (23.25±1.85mmHg) six months after injection (P=0.031). In 7 (37%) of the cases, progression to cataract was observed after treatment. After surgery, the visual acuity in all cases increased by 0.2 to 0.5. As a conclusion, intravitreal TA decreases of both the height and length of serous PED associated with AMD after 18 months follow-up in most cases. The presented data provides support for the hypothesis regarding the possibility of monotherapy of serous PED with intravitreal TA. |
format | Online Article Text |
id | pubmed-3939730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medical Hypothesis, Discovery & Innovation Ophthalmology |
record_format | MEDLINE/PubMed |
spelling | pubmed-39397302014-03-05 Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach V. Pasyechnikova, Nataliya A. Naumenko, Volodymyr R. Korol, Andrii S. Zadorozhnyy, Oleg B. Kustrin, Taras O. Nasinnyk, Illya Med Hypothesis Discov Innov Ophthalmol Research Article To evaluate the effects of intravitreal triamcinolone acetonide (TA) as a monotherapy of serous Pigment Epithelial Detachment (PED) associated with AMD (Age-Related Macular Degeneration), this study has been performed. Seventeen patients (19 eyes) with serous PED associated with AMD were observed. All patients received 0.1ml (4mg) of intravitreal TA. The mean follow-up period was 18 months. Re-attachment of serous PED was observed in 37% of cases to the end of follow-up. In other cases, the height and length of serous PED significantly decreased. Visual acuity remained stable in all cases. No evidence of RPE tear or CNV development were noted. Before TA administration, intraocular pressure (IOP) was 20.18 ± 2.58 mmHg however, after intravitreal TA, IOP increased gradually and reached its maximum of all period of observation (23.25±1.85mmHg) six months after injection (P=0.031). In 7 (37%) of the cases, progression to cataract was observed after treatment. After surgery, the visual acuity in all cases increased by 0.2 to 0.5. As a conclusion, intravitreal TA decreases of both the height and length of serous PED associated with AMD after 18 months follow-up in most cases. The presented data provides support for the hypothesis regarding the possibility of monotherapy of serous PED with intravitreal TA. Medical Hypothesis, Discovery & Innovation Ophthalmology 2012 /pmc/articles/PMC3939730/ /pubmed/24600628 Text en © 2012, Medical Hypothesis, Discovery & Innovation (MEHDI) Ophthalmology Journal This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article V. Pasyechnikova, Nataliya A. Naumenko, Volodymyr R. Korol, Andrii S. Zadorozhnyy, Oleg B. Kustrin, Taras O. Nasinnyk, Illya Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach |
title | Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach |
title_full | Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach |
title_fullStr | Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach |
title_full_unstemmed | Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach |
title_short | Serous Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration: A Possible Treatment Approach |
title_sort | serous pigment epithelium detachment associated with age-related macular degeneration: a possible treatment approach |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939730/ https://www.ncbi.nlm.nih.gov/pubmed/24600628 |
work_keys_str_mv | AT vpasyechnikovanataliya serouspigmentepitheliumdetachmentassociatedwithagerelatedmaculardegenerationapossibletreatmentapproach AT anaumenkovolodymyr serouspigmentepitheliumdetachmentassociatedwithagerelatedmaculardegenerationapossibletreatmentapproach AT rkorolandrii serouspigmentepitheliumdetachmentassociatedwithagerelatedmaculardegenerationapossibletreatmentapproach AT szadorozhnyyoleg serouspigmentepitheliumdetachmentassociatedwithagerelatedmaculardegenerationapossibletreatmentapproach AT bkustrintaras serouspigmentepitheliumdetachmentassociatedwithagerelatedmaculardegenerationapossibletreatmentapproach AT onasinnykillya serouspigmentepitheliumdetachmentassociatedwithagerelatedmaculardegenerationapossibletreatmentapproach |